Answers are grounded in this paper and cite their sources.
This review summarizes advancements in nano-integrated CRISPR-Cas systems for gene editing in cancer therapeutics, highlighting implications for clinical use.
While CRISPR-Cas9 enables precise targeting of cancer-driving genetic aberrations, its clinical application is impeded by instability, delivery inefficiencies, and immunogenicity. Nanotechnology addresses these challenges by engineering nanocarriers that facilitate enhanced cellular uptake, promote efficient endosomal escape, and ensure targeted delivery. This review summarizes current progress in nano-integrated CRISPR-Cas systems for cancer therapeutics, highlighting recent advancements in stimuli-responsive nanoplatforms for precise genome editing and their prospects for clinical application.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: